<DOC>
	<DOCNO>NCT00705588</DOCNO>
	<brief_summary>Pulmonary arterial hypertension chronic disease lung blood vessel result constriction high pressure . Treatment give variety drug include prostanoid class ( e.g . epoprostenol , iloprost phosphodiesterase 5 ( PDE-5 ) inhibitor ( e.g . sildenafil ) . Although drug know effective alone , little known combine together various combination . In trial add long-acting PDE-5 inhibitor treatment patient pulmonary arterial hypertension currently receive prostanoid drug .</brief_summary>
	<brief_title>Long Acting Phosphodiesterase 5 Inhibitors Add-on Therapy Patients With Pulmonary Hypertension Treated With Prostanoids .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>All patient must satisfy current diagnostic criterion pulmonary artery hypertension base historical right heart catheter data ( within 3 year study enrollment ) : Mean PAP &gt; 25mmHg rest &gt; 30mmHg exercise , PCWP &lt; 15mmHg PVR &gt; 3 Wood Units . Currently stable least 3 month prostanoid monotherapy ( epoprostenol iv iloprost inhale ) . Willing able participate study followup procedure . New York Heart Association ( NYHA ) Class IIIV . Six minute walk distance 100450 meter baseline assessment . Women childbearing age must demonstrate adequate contraception undergo pregnancy test . Patients congenital heart disease eligible inclusion . Functional Class NYHA Class I. PAH due chronic pulmonary thromboembolic disease , leave heart disease , chronic lung disease ( VC FEV1 &lt; 60 % predict ) chronic hypoxia . Acute intercurrent illness require hospital admission month proceed screen . Any nonPAH medical condition likely interfere participation evaluation study endpoint , e.g . musculoskeletal disorder . Any uncontrolled terminal nonPAH medical condition likely interfere completion study , accord judgment study physician . Concomitant therapy drug know interact adversely study drug . Chronic renal failure creatinine clearance &lt; 50ml/min calculated Cockcroft equation . Current participation another clinical trial . Pregnancy plan pregnancy study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>